c) intravenously administering the pharmaceutical composition to the human,

wherein the administration provides to the human from about 0.01 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute to about 0.1 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute,

wherein the human is hypotensive,

wherein the pharmaceutical composition exhibits less than about 5% degradation after storage at 2-8° C. for about four weeks.

2. The method of claim **1**, wherein the pharmaceutical composition further comprises SEQ ID NO: 2 in an amount of about 0.01% after storage for about 4 weeks at 2-8° C.

3. The method of claim **1**, wherein the pharmaceutical composition further comprises SEQ ID NO: 3 in an amount of about 0.01% after storage for about 4 weeks at 2-8° C.

4. The method of claim **1**, wherein the pharmaceutical composition further comprises SEQ ID NO: 4 in an amount of about 0.01% after storage for about 4 weeks at 2-8° C.

5. The method of claim **1**, wherein the human's mean arterial blood pressure is increased within 15 minutes of administration.

6. The method of claim **5**, wherein the human's hypotension is associated with vasodilatory shock.

7. The method of claim **6**, wherein the vasodilatory shock is post-cardiotomy shock.

8. The method of claim **6**, wherein the vasodilatory shock is septic shock.

9. The method of claim **8**, wherein the administration provides to the human from about 0.01 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute to about 0.07 units of vasopressin or the pharmaceutically-acceptable salt thereof per minute.

10. The method of claim **1**, further comprising attaining a target blood pressure in the human and continuing the administration for a period of about 8 hours.

11. The method of claim **10**, further comprising, after the period of about 8 hours, reducing the administration by about 0.005 units per minute.

12. The method of claim **1**, wherein the pharmaceutical composition is stored at about 5° C.

13. The method of claim **1**, wherein the pharmaceutical composition exhibits less than 1% degradation after storage at 2-8° C. for about four weeks.

14. The method of claim **1**, wherein the pharmaceutical composition is not lyophilized.

15. The method of claim **1**, wherein the pharmaceutical composition form is not frozen.

16. The method of claim **1**, wherein the pharmaceutical composition is diluted in a diluent prior to administration to the subject.

17. The method of claim **16**, wherein the pharmaceutical composition is diluted to a concentration of from about 0.21 μg/mL to about 2.1 μg/mL of vasopressin or the pharmaceutically acceptable salt thereof.

18. The method of claim **16**, wherein the diluent is 0.9% saline.

19. The method of claim **16**, wherein the diluent is 5% dextrose in water.

20. The method of claim **1**, wherein the pharmaceutical composition further comprises chlorobutanol.

* * * * *